Follow our progress

LONDON and RALEIGH, N.C., March 04, 2024 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces Mr. Andrew Fisher has today joined the Company as…

PDUFA Target Action Date for ensifentrine of June 26, 2024 Commercialization preparations advance Strong balance sheet supports commercialization and Company’s growth Conference call today at 9:00 a.m. EST / 2:00…

LONDON and RALEIGH, N.C., Feb. 15, 2024 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the fourth quarter and full year ended December 31, 2023 on Thursday, February 29, 2024 and host an investment

LONDON and RALEIGH, N.C., Feb. 01, 2024 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”) announces Mr. Michael Austwick has today joined the board as a Non-Executive Director….

LONDON and RALEIGH, N.C., Jan. 03, 2024 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces that senior management will present a company overview at…

Strengthens financial flexibility to support the Company’s continued growth LONDON and RALEIGH, N.C., Jan. 02, 2024 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), announces it and its…

LONDON and RALEIGH, N.C., Nov. 17, 2023 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces its President and CEO, David Zaccardelli, has won ‘Executive…

LONDON and RALEIGH, N.C., Nov. 08, 2023 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces that senior management will present a company overview at…

US FDA accepted NDA filing for ensifentrine for maintenance treatment of COPD PDUFA Target Action Date of June 26, 2024 Commercial launch preparations supported by strong balance sheet Conference call…